Search

Preventing blindness from diabetes: planning a programme of service development and research across Malawi

In sub-Saharan Africa 19.4 million people have diabetes; this is projected to rise to 28.6 million by 2030 [1]. Sight loss from diabetes devastates the lives of working people, affecting the financial stability of the families and communities who depend...

Building capacity for diabetic retinopathy services in Malawi

Screening for diabetic retinopathy prevents blindness. There is no systematic screening programme for diabetic eye disease in Malawi and people present when they have lost vision and it is too late for treatment. The aim of the VISION 2020 LINK...

Building leaders for eye care in Africa: the COECSA-RCOphth VISION 2020 LINK

The VISION 2020 LINK [1] between the College of Ophthalmology of Eastern, Central and Southern Africa (COECSA) and the Royal College of Ophthalmologists (RCOphth) has been building leaders of eye care in Africa since 2008, when a Memorandum of Understanding...

Commonwealth nations join forces to prevent blindness from diabetes

More than 70 representatives from 10 Commonwealth countries (in the African, Caribbean and Pacific regions) and Indonesia gathered at a five-day workshop in November 2014 to establish district or national plans to reduce blindness from diabetic retinopathy (DR). The event...

Real-world experience and outcomes of SLT laser used as a first-line treatment in ocular hypertension patients in a United Kingdom National Health Service setting

The management of raised intraocular pressure (IOP) in the context of ocular hypertension (OHT) and primary open angle glaucoma (POAG) remains a major contributor to the workload of ophthalmology units across the UK. Treatment of these conditions has historically centred...

Ophthalmic Aid to Eastern Europe (OAEE)

Peter Cackett, Tim ffytche and Dr Irina Gout reflect on historic ophthalmic aid sent to Eastern Europe. This article was written prior to the horrific events in Ukraine. An appeal for funds and equipment may be made by OAEE later...

Real world data of post-IVT endophthalmitis, from a nurse-delivered intravitreal injection service

Introduction Intravitreal injection of neutralising anti-vascular endothelial growth factor (VEGF) antibody was licenced more than a decade ago, and over the years there has been proportionate increase in the number of intravitreal injections [1]. Injection of a therapeutic agent through...

Safety and efficacy of a nurse-led intravitreal injection service using an Precivia® injection assist device

Nurse-led intravitreal injections have become of great importance for busy eye units. In this article, the authors present safety data from five years of a nurse-led service with the use of the Precivia® intravitreal injection assist device. Intravitreal injections of...

The ‘theatre of the mind’: Charles Bonnet Syndrome and Esme’s Umbrella

The founder of Esme’s Umbrella shares her experience with the poorly understood condition Charles Bonnet Syndrome and the creation of the campaign. Many years ago, when I was a young actress, I was in an American play called ‘Butterflies are...

The role of injection assistant devices in establishing a nurse-led AMD service

The author shares his experience of setting up a nurse-led service to deliver anti-VEGF intravitreal injections and how injection assistant devices supported training. Age-related macular degeneration (AMD) has become a leading cause of irreversible blindness [1]. It is estimated that...

Optical coherence tomography – reinventing the eye examination

It has been 25 years since Huang et al. presented the first optical coherence tomography (OCT) images in Science [1]. With vast improvements in OCT technology over the years, it is now possible to acquire high-resolution cross-sectional images of the...

Regulatory drug evaluations and expedited review initiatives: EU and US perspectives

The European Medicines Agency (EMA) and United States Food and Drug Administration (FDA) each conduct independent assessments of benefit-risk profile when evaluating applications to market new or modified medicines, and their respective decision-making is guided by distinct legislation, procedures and...